News

Categories

April 29, 2026

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA

April 27, 2026

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

April 21, 2026

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

April 17, 2026

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

April 16, 2026

Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

April 9, 2026

Zymeworks to Present at the AACR Oncology Industry Partnering Event

April 9, 2026

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

April 1, 2026

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

March 30, 2026

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

March 24, 2026

Zymeworks Announces Participation in Upcoming Investor Conferences

March 18, 2026

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

March 17, 2026

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting